MEDTECH: Separating the wheat from the chaff

MedTech, which has historically been a defensive sector, has once again stood its ground even as broader markets have been rattled by the pandemic.

But, digging into the details throws up interesting trends: the resilience is underpinned by clear extremes.

Hence, leveraging the right opportunities assumes a greater importance and is critical to outperformance.

At the upcoming webinar, we will dissect these conflicting trends and share some interesting stock ideas that are best suited to win in a COVID-stricken world.

AlphaValue’s analysts on the sector, Sumit Sayal, Virendra Chauhan and Martin Schnee, Ph.D., just released a new strategy piece on European Medtech companies, including : BioMérieux, Qiagen, Sartorius Stedim, Sartorius, Getinge, and Siemens Healthineers.

Access to report : click here

Subscribe to our blog


Let’s talk
Interested in our research and want to learn more?
Alphavalue Morning Market Tip
Potential disposal of Eastern Europe business.
A $330 share price, 40x earnings expected five years from now, and growth funded by SoftBank: wh...
European defence is no longer the cozy oligopoly it once was. Rising competition from AI-driven sta...